Synthego and Vita Therapeutics License hfCas12Max CRISPR
Synthego and Vita Therapeutics, Inc. announced a licensing agreement to integrate Synthego’s high-fidelity hfCas12Max CRISPR system into Vita’s cell therapeutic programs. This nonexclusive sublicense grants Vita Therapeutics access to...